ClinicalTrials.gg
RecruitingNCT07574047Updated Oct 27, 2026

MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma.

A Phase 2 interventional study of Immune Checkpoint Inhibitors and Immune Checkpoint Inhibitors in Melanoma and Advanced Melanoma, sponsored by Swiss Cancer Institute. Recruiting at 9 sites in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Swiss Cancer Institute · Phase 2, Interventional, and Treatment

How we know · 5 judgments

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 27, 2026Now RecruitingStart date moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 499 studies testing Immune checkpoint inhibitors in Melanoma — 90 open to participants now, 175 under way, 24 of them phase 3. A drug class: Immune checkpoint inhibitors · Melanoma.

Planned enrollment
143rd of 496
108 · median 50
Started
2026
with 22 others
Phase 2
233 of 499
47 open now
Primary completion
2030-06
later than 163 of 174 live
Registered
491st of 499
by date

Among the 499 studies testing Immune checkpoint inhibitors in Melanoma, this one is the 143rd largest by planned enrollment of the 496 interventional ones that give a count, is one of 23 that started in 2026, is one of 233 in phase 2, reaches primary completion later than 163 of the 174 other live ones, and was the 491st registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.

Browse Melanoma studies →

Open to participants now

90 of the 499 studies testing Immune checkpoint inhibitors in Melanoma are open now, in 12 countries. Recruiting first, the newest first:

84 more — sign in →

By country, each count listing its studies:

All 90 open studies →

About Immune checkpoint inhibitors

A class of medicines: which ones, and the studies of each, are on its page →

Who these studies take

Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 499 studies testing Immune checkpoint inhibitors in Melanoma, or all of them as a file.
02

Study summary

Melanoma remains a common cancer with rising incidence, and despite significant improvements with immune checkpoint inhibitors (ICIs), clinical outcomes remain heterogeneous. Retrospective analyses across multiple tumor types, including melanoma, suggest that earlier daytime administration of ICIs may enhance therapeutic effectiveness, potentially due to circadian modulation of immune function. A pronounced survival benefit has been observed particularly among female patients receiving earlier infusions. This trial prospectively evaluates whether aligning ICI administration with circadian immune activity can improve outcomes in melanoma and support the development of sex-specific optimization of immunotherapy.

Read the detailed description

The introduction of ICIs a decade ago revolutionized the treatment of various malignancies, particularly melanoma. Yet treatment responses are heterogenous and depend on patient characteristics such as sex and age, and tumor characteristics. The relationship between sex and ICI response in melanoma is complex and may be influenced by various factors, including the type of ICI, tumor mutation burden, presence of infiltrating immune cells, microbiome, and concomitant medications affect the immune system's ability to mount antitumor responses. While some retrospective data indicate poorer outcomes for female patients, in other real-world reports female sex is associated with better outcomes. Prospective, sex-stratified clinical studies are necessary to provide a definitive answer and to integrate sex as a critical variable in personalizing melanoma treatment strategies. Temporal variations in antibody responses and anticancer immunity after vaccination have been reported in both humans and mice. Circadian rhythms also remain an important regulator of immune cell activities. The optimal time for inducing adaptive immune responses consistently appears to be situated around or just before behavioral activity; for nocturnal mice this optimal window appears to be the afternoon, while in diurnal humans this may be the early morning. However, the optimal time of day for ICI administration is currently unknown. A retrospective single-center analysis of advanced melanoma patients showed that receiving less than 20% of the ICI infusions after 16h30 was associated with enhanced overall survival. In subgroup analyses, female patients had a significantly longer OS when less than 20% of the treatment was administered after 16h30.

Optimizing the timing of ICI therapy to target the immune system at the time of its highest sensitivity could significantly improve patient outcomes, particularly for female patients, without exposing patients to additional drugs and generating additional toxicity and costs. Given the limitations of retrospective analyses, a prospective randomized trial is essential to obtain results that could potentially change clinical practice.

03

Conditions studied

  • Melanoma
  • Advanced Melanoma

Browse trials for

Keywords

  • Advanced melanoma
  • chrono-immunotherapy
  • phase IV
  • Nivolumab
  • Ipilimumab
  • relatlimab
  • Pembrplizumab
  • Opdivo
  • Keytruda
  • Opdualag
  • Yervoy
  • immune checkpoint inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written according to Swiss law and ICH GCP E6 regulations before registration and prior to any trial specific procedures.
  • confirmed unresectable cutaneous stage III or stage IV melanoma. Note: Participants with central nervous system (CNS) are eligible.
  • Participants with a previously treated other are eligible, if the risk of the prior malignancy interfering with either safety or efficacy endpoints is very low.
  • Measurable or evaluable disease.
  • Age ≥ 18 years.
  • Patients deemed suitable for ICI therapy based on the local investigator's clinical assessment.
  • performance status 0-2.
  • Women of must use effective , not be pregnant or lactating and agree not to become pregnant during trial treatment and until 5 months after the last dose of trial treatment. A negative pregnancy test before inclusion into the trial is required for all women of childbearing potential.
  • Men agree not to donate sperm or to father a child during trial treatment and until 5 months after the last dose of trial treatment.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with any systemic anti-cancer therapy; with the exception of prior adjuvant or BRAF/MEK inhibitor therapy if the time from last dose to recurrence is more than 6 months.
  • Recent treatment (within 28 days prior to first dose) with any experimental drug.
  • Known history of allogeneic organ transplant.
  • Uveal or mucosal melanoma.
  • Receipt of within 28 days prior to first dose.
  • Any concomitant drugs for use with the trial drugs according to the approved product information.
  • Known to trial drug(s) or to any component of the trial drug(s).
  • Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the investigator may interfere with the planned staging, treatment and follow-up, affect participant compliance or place the participant at high risk from treatment-related complications.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
108 participants (estimated)

Study arms

  • Experimental
    ICI Infusions 8-12 h

    Participants will be randomized 1:1 to receive standard-of-care ICI therapy in an early (08:00 - 12:00) infusion time window.

    Drug: Immune Checkpoint Inhibitors

  • Active comparator
    ICI Infusions 15-18 h

    Participants will be randomized 1:1 to receive standard-of-care ICI therapy in a late (15:00 - 18:00) infusion time window.

    Drug: Immune Checkpoint Inhibitors

Interventions

  • Morning administration of ICI per physician's choice, according to local practice: Nivolumab (Opdivo®) Monotherapy - 240 mg administered intravenously every 2 weeks (Q2W) Pembrolizumab (Keytruda®) Monotherapy \- 200 mg administered intravenously every 3 weeks (Q3W) Ipilimumab (Yervoy®) + Nivolumab (Opdivo®) Combination Therapy * Induction Phase: * Ipilimumab 3 mg/kg intravenously every 3 weeks (Q3W) * Nivolumab 1 mg/kg intravenously every 3 weeks (Q3W) * Administered for 4 cycles * Maintenance Phase: * Nivolumab 240 mg administered intravenously every 2 weeks (Q2W) Nivolumab + Relatlimab Fixed-Dose Combination (Opdualag®) Nivolumab 480 mg and relatlimab 160 mg administered intravenously every 4 weeks (Q4W)

  • Afternooon administration of ICI per physician's choice, according to local practice: Nivolumab (Opdivo®) Monotherapy - 240 mg administered intravenously every 2 weeks (Q2W) Pembrolizumab (Keytruda®) Monotherapy \- 200 mg administered intravenously every 3 weeks (Q3W) Ipilimumab (Yervoy®) + Nivolumab (Opdivo®) Combination Therapy * Induction Phase: * Ipilimumab 3 mg/kg intravenously every 3 weeks (Q3W) * Nivolumab 1 mg/kg intravenously every 3 weeks (Q3W) * Administered for 4 cycles * Maintenance Phase: * Nivolumab 240 mg administered intravenously every 2 weeks (Q2W) Nivolumab + Relatlimab Fixed-Dose Combination (Opdualag®) Nivolumab 480 mg and relatlimab 160 mg administered intravenously every 4 weeks (Q4W)

This study also gives PembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., NivolumabStudies of NivolumabNivolumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., IpilimumabStudies of IpilimumabIpilimumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS)

    Progression-free survival (PFS), defined as time from randomization to progression according to local assessment or death. Participants not experiencing an event will be censored at the date of the last available assessment before initiation of a new anti-cancer treatment, if any.

    Time frame: From randomization to Progressive Desease or death, up to 6 years

Secondary outcomes

  1. Overall survival (OS)

    OS is defined as the time from randomization until death due to any cause. Participants not experiencing an event will be censored at the last date they were known to be alive.

    Time frame: From randomization to death, up to 6 year

  2. Objective response rate (ORR)

    Objective response rate (ORR) Objective response is defined as any complete response (CR) or partial response (PR) according to local assessment achieved during treatment. Any participant with CR or PR as best observed response during treatment will be considered as a success; otherwise, they will be considered as a failure. Participants without any tumor assessment, or with non-evaluable response (NE) during treatment, will be considered as failures for this endpoint.

    Time frame: At the end of trial treatment, up to 4 years from registration

07

Study locations

9 of 9 sites recruiting
08

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Jun 2030, 44 months after the start.

Of 277 non-industry phase 2 interventional studies under Melanoma, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 94. This study's planned 44 months is below that.

Counting every sponsor, half of 383 studies reached it within 53 months; a quarter within 32 and three quarters within 88.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Oct 14, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2026
First posted
May 7, 2026
StartActual
Oct 12, 2026was Sep 2026
Primary completionEst.
Jun 2030
CompletionEst.
Jun 2032
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 13, 2026
Sites
1 site added. 8 sites changed recruiting status (8 now recruiting)
Show 8 sites
  • HFR Fribourg · Fribourg, Switzerlandno status→Recruiting
  • Ente Ospedaliero Cantonale (EOC) · Bellinzona, Switzerlandno status→Recruiting
  • Inselspital, Bern · Bern, Switzerlandno status→Recruiting
  • Hôpitaux Universitaires de Genève HUG · Geneva, Switzerlandno status→Recruiting
  • Centre Hospitalier Universitaire Vaudois (CHUV) · Lausanne, Switzerlandno status→Recruiting
  • Spital Thurgau (Kantonsspital Münserlingen und Frauenfeld) · Münsterlingen, Switzerlandno status→Recruiting
  • HOCH Health Ostschweiz - Kantonsspital St. Gallen · Sankt Gallen, Switzerlandno status→Recruiting
  • Universitätsspital Zürich USZ · Zurich, Switzerlandno status→Recruiting
Show site
  • Universitätsspital Basel · Basel, Switzerland
across 2 updates, Oct 13, 2026 – Oct 27, 2026
Start date
Sep 21, 2026→Oct 12, 2026 (actual)
Oct 14, 2026
Site contacts
Changed at 3 sites. See the sites
Show 3 sites
  • Hôpitaux Universitaires de Genève HUG · Geneva, SwitzerlandContact added a•••@hug.ch · •••9862Contact added (no phone or email listed)
  • Centre Hospitalier Universitaire Vaudois (CHUV) · Lausanne, SwitzerlandContact person changed (no phone or email listed)
  • Universitätsspital Zürich USZ · Zurich, SwitzerlandContact added j•••@usz.ch · •••1111Contact added (no phone or email listed)
Oct 27, 2026
Show all 3 updates
  1. Oct 27, 2026
    1 site added
    Show site
    • Universitätsspital Basel · Basel, Switzerland
    Site contacts Changed at 3 sites. See the sites
    Show 3 sites
    • Hôpitaux Universitaires de Genève HUG · Geneva, SwitzerlandContact added a•••@hug.ch · •••9862Contact added (no phone or email listed)
    • Centre Hospitalier Universitaire Vaudois (CHUV) · Lausanne, SwitzerlandContact person changed (no phone or email listed)
    • Universitätsspital Zürich USZ · Zurich, SwitzerlandContact added j•••@usz.ch · •••1111Contact added (no phone or email listed)
  2. Oct 14, 2026
    Start date Sep 21, 2026→Oct 12, 2026 (now actual)
  3. Oct 13, 2026
    Not yet recruiting→Recruiting
    8 sites changed recruiting status (8 now recruiting)
    Show 8 sites
    • HFR Fribourg · Fribourg, Switzerlandno status→Recruiting
    • Ente Ospedaliero Cantonale (EOC) · Bellinzona, Switzerlandno status→Recruiting
    • Inselspital, Bern · Bern, Switzerlandno status→Recruiting
    • Hôpitaux Universitaires de Genève HUG · Geneva, Switzerlandno status→Recruiting
    • Centre Hospitalier Universitaire Vaudois (CHUV) · Lausanne, Switzerlandno status→Recruiting
    • Spital Thurgau (Kantonsspital Münserlingen und Frauenfeld) · Münsterlingen, Switzerlandno status→Recruiting
    • HOCH Health Ostschweiz - Kantonsspital St. Gallen · Sankt Gallen, Switzerlandno status→Recruiting
    • Universitätsspital Zürich USZ · Zurich, Switzerlandno status→Recruiting
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07574047
Lead sponsor
Swiss Cancer Institute
Responsible party
Sponsor
First posted
May 7, 2026
Start date
Oct 12, 2026
Primary completion
Jun 2030 (estimated)
Completion
Jun 2032 (estimated)
Last update
Oct 27, 2026

Study contacts

Lenka Vokalova, PhD
Contact
trials@swisscancerinstitute.ch
+41 31 389 91 91
Christina Müller, PhD
Contact
trials@swisscancerinstitute.ch
+41 31 389 91 91
Berna Özdemir, MD PhD
study chair · Insel Gruppe AG, University Hospital Bern

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Immune checkpoint inhibitors · Pembrolizumab · Nivolumab · Ipilimumab

Start the discussion